Bristol Myers Squibb is purchasing an Nvidia DGX SuperPOD built on the chipmaker's Vera Rubin architecture to support artificial intelligence use across its drug discovery and development operations.
Nvidia introduced the architecture earlier this year, which promises significant performance gains for AI workloads. The DGX SuperPOD is a high-end server that can handle complex machine learning tasks, allowing companies like Bristol Myers Squibb to move away from traditional computing methods.
The company's acquisition of the Nvidia system marks the first time a life sciences group will use a DGX SuperPOD based on Vera Rubin architecture. This partnership is likely to enhance Bristol Myers Squibb's AI capabilities, enabling more efficient and effective drug discovery processes. The integration of this technology into their operations will enable the company to accelerate innovation in its pharmaceutical pipeline.